Clinical Trial

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma

Study acronym: BELI(E)VE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the safety and efficacy of the drug combination belantamab mafodotin and venetoclax, with or without the addition of dexamethasone, in patients with relapsed/refractory multiple myeloma bearing the translocation t(11;14)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-05-10; most recent amendment 2026-05-14.
Status change: Not Yet Recruiting → Recruiting 2023-07-17
Trial Details
NCT Number NCT05853965
Lead Sponsor Universitätsklinikum Hamburg-Eppendorf
Conditions Multiple Myeloma, Multiple Myeloma in Relapse
Enrollment 45 participants
Start Date 2023-06-28
Primary Completion 2027-04 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-18